CTI Science

Lexington, United States Founded: 2007 • Age: 19 yrs Acquired By EmeraMed
Focused on the development of therapeutics for the treatment of drug toxicity
Annual revenue - Latest available
Total funding $4.0M 2 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About CTI Science

CTI Science is a company based in Lexington (United States) founded in 2007 was acquired by EmeraMed in July 2014. CTI Science has raised $3.97 million across 2 funding rounds from investors including EmeraMed. CTI Science offers products and services including Emeramide and Early Access Program.

  • Headquarter Lexington, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Emeramed Ltd
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $3.97 M (USD)

    in 2 rounds

  • Latest Funding Round
    $271 K (USD), Series A

    Jan 16, 2014

  • Investors
  • Employee Count
    Not available
  • Acquired by
    EmeraMed

    (Jul 01, 2014)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of CTI Science

CTI Science offers a comprehensive portfolio of products and services, including Emeramide and Early Access Program.

Product name locked
Category locked
Primary

A drug that chelates heavy metals and reduces oxidative stress in the body.

Product name locked
Category locked
Locked

Program providing access to Emeramide for patients before full approval.

Funding Insights of CTI Science

CTI Science has successfully raised a total of $3.97M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $271 thousand completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in CTI Science

CTI Science has secured backing from 1 investor. Prominent investors backing the company include EmeraMed.

All
Investor Description Founded Year Domain Location
Therapeutics for mercury toxicity treatment are developed by EmeraMed.
Locked Locked Locked
Premium access

Investor details for CTI Science

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CTI Science

Investments
Premium access

Investment portfolio details for CTI Science

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - CTI Science

Premium access

Detailed financials for CTI Science

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cti Science Comparisons

CTI Science Primary company
Description
Focused on the development of therapeutics for the treatment...
Location
Lexington, United States
Founded Year
2007
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for CTI Science

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of CTI Science

Premium access

Detailed competitors of CTI Science

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cti Science

Premium access

Complete news archive for CTI Science

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CTI Science

CTI Science was founded in 2007 and raised its 1st funding round 6 years after it was founded.

CTI Science is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.

CTI Science is a funded company, having raised a total of $3.97M across 2 funding rounds to date.

CTI Science, formerly known as Chelator Technologies produces dietary antioxidants that maintain healthy glutathione levels in the body. They developed OSR1 which is an antioxidant product that scavenges free radicals and helps maintain healthy glutathione levels. Pharmacies halted the sales of this product six weeks after the U.S. Food and Drug Administration called the product an unapproved new drug.The company was later acquired by ERMES Medical in July 2014.

CTI Science offers Emeramide and Early Access Program.

CTI Science has 1 investor. Key investors include EmeraMed.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available